Stockscreener 앱 받기
0.73
2.82%
0.02
시장 영업 전:
.77
0.04
+5.48%
전일 마감가:
$0.71
열려 있는:
$0.71
하루 거래량:
109.34K
Relative Volume:
0.57
시가총액:
$24.38M
수익:
-
순이익/손실:
$-10.21M
주가수익비율:
-1.2496
EPS:
-0.5842
순현금흐름:
-
1주 성능:
+1.25%
1개월 성능:
-15.06%
6개월 성능:
-41.13%
1년 성능:
-31.13%
1일 변동 폭
$0.71
$0.7499
1주일 범위
$0.6839
$0.7499
52주 변동 폭
$0.63
$2.60
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Compare NRSN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
0.73 | 23.71M | 0 | -10.21M | 0 | -0.5842 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Neurosense Therapeutics Ltd 주식(NRSN)의 최신 뉴스
Form 20-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)] - ADVFN
Sentiment Review: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changesPortfolio Gains Summary & Community Verified Swing Trade Signals - baoquankhu1.vn
Nasdaq Moves: Is NeuroSense Therapeutics Ltd Equity Warrant showing insider buyingPortfolio Value Report & Real-Time Sentiment Analysis - baoquankhu1.vn
Patterns Watch: Is NeuroSense Therapeutics Ltd Equity Warrant part of any ETF2026 Top Decliners & Real-Time Price Movement Reports - baoquankhu1.vn
If You Invested $1,000 in Neurosense Therapeutics Ltd (NRSN) - Stock Titan
Trend Report: Is NeuroSense Therapeutics Ltd Equity Warrant showing insider buyingWeekly Risk Report & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Bank Watch: Is NeuroSense Therapeutics Ltd Equity Warrant showing insider buyingMarket Weekly Review & Daily Stock Trend Reports - baoquankhu1.vn
Chipmakers Recap: Why is NeuroSense Therapeutics Ltd stock going downEarnings Growth Summary & Weekly Market Pulse Alerts - baoquankhu1.vn
Aug Highlights: What are NeuroSense Therapeutics Ltd Equity Warrants earnings expectations2026 Earnings Surprises & Low Risk Entry Point Tips - baoquankhu1.vn
NRSN Analyst Rating Update: D. Boral Capital Maintains 'Buy' Rat - GuruFocus
Inflation Data: Is NeuroSense Therapeutics Ltd Equity Warrant stock undervalued right nowEarnings Summary Report & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Volatility Watch: Can NeuroSense Therapeutics Ltd Equity Warrant keep up with sector leaders2026 Price Momentum & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Breakout Watch: Is NeuroSense Therapeutics Ltd gaining market share2026 Review & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Roth MKM Maintains NeuroSense Therapeutics(NRSN.US) With Buy Rating, Maintains Target Price $3 - Moomoo
Income Plays: Is NeuroSense Therapeutics Ltd stock a value trap2026 AllTime Highs & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Is NeuroSense Therapeutics Ltd stock a buy or sellMarket Trend Report & Weekly Consistent Profit Watchlists - baoquankhu1.vn
NeuroSense granted Brazilian patent covering PrimeC composition - TipRanks
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements - marketscreener.com
NeuroSense Wins Long-Term Brazilian Patent Protection for ALS Drug PrimeC - TipRanks
NeuroSense Granted Brazilian Patent Covering PrimeC Composition - Bitget
Form 6-KReport of foreign issuer [Rules 13a-16 and 15d-16] - ADVFN
NeuroSense Therapeutics Faces Nasdaq Deficiency Notices but Retains Listing Status - The Globe and Mail
NRSN PE Ratio & Valuation, Is NRSN Overvalued - Intellectia AI
NeuroSense Therapeutics Ltd. (NRSN) stock price, news, quote and history - Yahoo Finance UK
NeuroSense Therapeutics Receives Nasdaq Notifications on Compliance Issues - National Today
NeuroSense Faces Nasdaq Compliance Warning - Intellectia AI
Nasdaq flags NeuroSense (NRSN) for bid price and $35M value shortfall - Stock Titan
NeuroSense Therapeutics Ltd. Stock Forecast Summary - Meyka
NRSN’s $1.00 Bid Price Requirement Serves as Key Trigger for Meeting Compliance and Raising Capital - Bitget
NeuroSense (NRSN) CFO awarded 200,000 restricted shares vesting over 2 years - Stock Titan
NeuroSense (NRSN) CFO Or Eisenberg reports 573,126 shares and warrants on Form 3 - Stock Titan
Free cash flow per share of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
NeuroSense Therapeutics Posts 2025 Results as PrimeC Advances Toward Phase 3 ALS Trial - TipRanks
NeuroSense Therapeutics (NRSN) director details options and restricted shares - Stock Titan
NeuroSense (NRSN) 2025 20-F: cash squeeze, going concern and PrimeC ALS plans - Stock Titan
NeuroSense Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update - Nasdaq
Market Pulse: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changes2026 Chart Watch & Growth Focused Stock Pick Reports - baoquankhu1.vn
NeuroSense (NRSN) CTO awarded 200,000 restricted shares vesting over two years - Stock Titan
NeuroSense (NASDAQ: NRSN) CTO discloses options, shares and RSU awards - Stock Titan
NeuroSense (NRSN) CEO details substantial share and warrant holdings - Stock Titan
NeuroSense Therapeutics (NASDAQ: NRSN) grants GM Hagit Binder 200,000 shares - Stock Titan
NeuroSense Therapeutics Ltd. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Risk Report: Is NeuroSense Therapeutics Ltd Equity Warrant forming a bullish divergence2026 Major Catalysts & AI Driven Price Predictions - baoquankhu1.vn
NeuroSense Therapeutics (NASDAQ:NRSN) Receives “Buy” Rating from D. Boral Capital - Defense World
Market Fear: What are NeuroSense Therapeutics Ltd Equity Warrants recent SEC filings showingEarnings Recap Summary & Daily Entry Point Trade Alerts - baoquankhu1.vn
NeuroSense Therapeutics (NRSN): Analyst Reaffirms 'Buy' Rating | - GuruFocus
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout - Finviz
NeuroSense Reschedules Health Canada Meeting as PrimeC Data Package Strengthens - TipRanks
[6-K] NeuroSense Therapeutics Ltd. Current Report (Foreign Issuer) | NRSN SEC FilingForm 6-K - Stock Titan
Neurosense Therapeutics Ltd (NRSN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):